Pangea Biomed
Description
Founded in 2018, Pangea Biomed has developed ENLIGHT – the world’s most advanced multi-cancer, multi-therapy response predictor.
ENLIGHT combines AI, machine learning, and deep RNA analysis from RNAseq or digitized H&E slide images (digital pathology) to generate tumor molecular signatures and predict response. Our approach is unsupervised, which means we don’t require access to our partner’s clinical data to develop the first version of our biomarker. This unique feature allows us to save clinical efficacy data for validation.
We collaborate with both clinical and preclinical-stage pharma companies. For clinical-stage programs, we develop superior biomarkers for an optimal patient recruitment strategy, and for preclinical programs, we build a biomarker that can inform the selection of the best preclinical model for your asset's proof of concept validation. It can also help determine the most appropriate PDX model on which the asset should be tested. Our partners range from big pharma to small/midsize biotech companies.
Pangea has also developed multiple collaborations with research and clinical institutes, including the NCI, Sheba and Hadassah hospitals.
Pangea is backed by NFX, and validations of our technology have been published in leading journals, such as Nature Cancer, Med, Cell, Science Advances, Cancer Cell and Nature Communications. Pangea's founders are world-leading cancer researchers, holding senior positions in organizations such as the NIH and MD Anderson.
Company members
Emmanuel Elalouf
